Nieva Shares Background on the IMpower010 Study
Jorge Nieva, MD, discusses the backgroup to the IMpower010 study, the results of which were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
Jorge Nieva, MD, of USC Norris Comprehensive Cancer Center, discusses the backgroup to the IMpower010 study (NCT02486718), the results of which were presented at the 2021 American Society of Clinical Oncology Annual Meeting.
According to Nieva, there has been a revolution in immunotherapy in the last decade. The Nobel Prize was awarded for the discovery of checkpoint inhibitors, which, according to Nieva, were able to effect cures in previously incurable patients with advanced disease.
Due to the success of immunotherapy in later line stages of disease, efforts have been made to see if these agents are efficacious in earlier lines and earlier stage disease.
According to Nieva, IMpower010 found the chance of replace was reduced with immunotherapy. However questions around if these agents should be used in earlier lines or if they should be reserved for later remain.
